Table 3. Multivariate analysis of late relapses up to 5 years after HCT.
| N | RR | 95% CI | p-value | ||
|---|---|---|---|---|---|
| AML Patients | |||||
| No cGVHD | 1424 | 1.00 | |||
| cGVHD | 1117 | 0.93 | 0.75 | 1.14 | 0.4809 |
| ALL patients | |||||
| No cGVHD | 1056 | 1.00 | |||
| cGVHD | 742 | 1.09 | 0.87 | 1.37 | 0.4423 |
| CML patients | |||||
| No cGVHD | 1154 | 1.00 | |||
| cGVHD | 1344 | 0.47 | 0.37 | 0.59 | <0.0001 |
| MDS patients | |||||
| No cGVHD | 302 | 1.00 | |||
| cGVHD | 350 | 1.12 | 0.70 | 1.79 | 0.6391 |
| Acute GVHD | <0.0001 | ||||
| none | 4051 | 1.00 | |||
| aGVHD in first 29 days after HCT | 2446 | 0.74 | 0.63 | 0.85 | <0.0001 |
| aGVHD after day 29 after HCT | 986 | 1.15 | 0.96 | 1.37 | 0.1223 |
| Disease Status at transplant | <.0001 | ||||
| Early | 4661 | 1.00 | |||
| Intermediate | 1823 | 1.57 | 1.35 | 1.83 | <0.0001 |
| Advanced | 999 | 2.57 | 2.13 | 3.10 | <0.0001 |
| HLA Status | 0.0200 | ||||
| Sibling Donor | 1861 | 1.00 | |||
| Well Matched Unrelated | 1412 | 0.83 | 0.69 | 0.99 | 0.0370 |
| Partially matched Unrelated | 1369 | 0.78 | 0.65 | 0.93 | 0.0049 |
| Poorly matched Unrelated | 841 | 0.85 | 0.69 | 1.04 | 0.1143 |
| GVHD prophylaxis | 0.0043 | ||||
| T-cell depletion | 748 | 1.00 | |||
| Cyclosporine±methotrexate±other | 5738 | 0.75 | 0.62 | 0.91 | 0.0032 |
| Tacrolimus±methotrexate±other | 997 | 0.68 | 0.53 | 0.88 | 0.0026 |
Factors tested, but not listed in table: Recipient age, sex, graft type, donor-recipient gender mismatch, donor parity, donor-recipient CMV serology, use of TBI, use of ATG, aGVHD grade, year of transplant, platelet count at cGVHD diagnosis, serum bilirubin at cGVHD diagnosis, type of cGVHD onset, KPS/L at cGVHD diagnosis, severity of cGVHD at 1 year post-transplant, organ involvement of cGVHD at 1 year post-transplant